MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*.
CardioFocus® Announces Initiation of HeartLight® X3 Clinical Evaluation
MARLBOROUGH, Mass., February 26, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced the initiation of a clinical evaluation of the new HeartLight X3 System for the treatment of AF.
CardioFocus® Announces Expanded Partnership With Japan Lifeline
MARLBOROUGH, Mass., January 9, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that it has entered into an expanded partnership with Japan Lifeline Co., Ltd. (JLL).
CardioFocus® Completes Successful Controlled U.S. Commercial Launch Of The HeartLight® System
MARLBOROUGH, Mass., November 29, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the successful completion of its controlled U.S. commercial launch of the HeartLightEndoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF).
MARLBOROUGH, Mass., September 27, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF).
MARLBOROUGH, Mass., July 31, 2017 /PRNewswire/ — CardioFocus, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF) in Japan.
MARLBOROUGH, Mass., Mar. 29, 2017 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical studies currently underway. Collectively, up to 1,000 AF patients will be […]
Na Homolce Hospital Treats 500th Patient Using HeartLight Endoscopic Ablation System
MARLBOROUGH, Mass., June 6, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the electrophysiology team at Na Homolce Hospital in Prague, Czech Republic is the first to successfully treat 500 patients using the HeartLight® Endoscopic Ablation System.
CardioFocus® Completes $20 Million Equity Financing
MARLBOROUGH, Mass., Mar. 29, 2017 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced the completion of a $20 million round in equity financing.
CardioFocus, Inc. today announced the initial clinical evaluation of the HeartLight® Excalibur Balloon™, a next-generation technology designed for the treatment of atrial fibrillation (AF). The Excalibur Balloon leverages the proven universal balloon design of the HeartLight Endoscopic Ablation System and introduces an advanced feature set that optimizes the speed and magnitude of target tissue contact during pulmonary vein isolation (PVI) procedures.